Table 1.
Demographic characteristics, surgical features, type of tumor, contrast enhancement and histopathological features of patients in the cLGG and iLGG groups.
| Demographic Characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|
| cLGG |
iLGG |
p-value | ||||||
| Grade 2 |
Grade 3 |
Total |
Grade 2 |
Grade 3 |
Total |
|||
| n = 27 | n = 3 | n = 30 | n = 73 | n = 62 | n = 135 | |||
| Age (mean ± SD) | 31.1 ± 8.1 | 34.2 ± 4.9 | 31.4 ± 7.9 | 36.1 ± 9.9 | 39.7 ± 13.2 | 37.9 ± 11.6 | 0.004 | |
| Gender | Male | 22 | 3 | 25 (83.3%) | 53 | 39 | 93 (68.9%) | 0.443 |
| Female | 5 | 0 | 5 (16.7%) | 20 | 22 | 42 (31.1%) | ||
|
Average Length of Stay (days) |
1.7 |
1 |
1.6 |
2.2 |
2.1 |
2.2 |
0.207 |
|
| Surgical characteristics | ||||||||
| cLGG | iLGG | |||||||
| Grade 2 | Grade 3 | Total | Grade 2 | Grade 3 | Total | |||
| N (% within grade) |
N (% within grade) |
N (% within cLGG) |
N (% within grade) |
N (% within grade) |
N (% within iLGG) |
|||
| Gross total resection | 7 (43.8) | 3 (100.0) | 10 (52.6) | 22 (37.9) | 20 (46.5) | 42 (41.6) | ||
| Sub-total resection | 8 (50.0) | 0 (0.0) | 8 (42.1) | 34 (58.6) | 22 (51.2) | 56 (55.4) | ||
| Biopsy | 1 (6.3) | 0 (0.0) | 1 (5.3) | 2 (3.4) | 1 (2.3) | 3 (3.0) | ||
|
Blood loss (mean, in ml) |
263.8 ± 130.2 |
370 |
270 ± 128 |
404.4 ± 270.1 |
419.6 ± 210.3 |
410.6 ± 246.0 |
||
| Tumor type | ||||||||
| cLGG | iLGG | |||||||
| Grade 2 | Grade 3 | Total | Grade 2 | Grade 3 | Total | |||
| N (% within grade) |
N (% within grade) |
N (% within cLGG) |
N (% within grade) |
N (% within grade) |
N (% within iLGG) |
|||
| Oligodendroglioma | 18 (66.7) | 2 (66.7) | 20 (70) | 56 (80.0) | 34 (56.7) | 90 (69) | ||
|
Astrocytoma |
9 (33.3) |
1 (33.3) |
10 (30) |
14 (20.0) |
26 (43.3) |
40 (31) |
||
| Contrast enhancement | ||||||||
| cLGG | iLGG | |||||||
| Grade 2 | Grade 3 | Total | Grade 2 | Grade 3 | Total | |||
| N (%) |
N (%) |
N |
N (%) |
N (%) |
N |
|||
| None | 13 (54.2) | 1 (33.3) | 14 | 17 (24.6) | 11 (18.6) | 28 | ||
| Subtle | 10 (41.7) | 1 (33.3) | 11 | 45 (65.2) | 33 (55.9) | 78 | ||
| Definite | 1 (4.2) | 1 (33.3) | 2 | 3 (4.3) | 11 (18.6) | 14 | ||
|
Intense |
0 (0.0) |
0 (0.0) |
0 |
4 (5.8) |
4 (6.8) |
8 |
||
| Histopathological features | ||||||||
| cLGG | iLGG | |||||||
| Grade 2 | Grade 3 | Total | Grade 2 | Grade 3 | Total | |||
| N (% within grade) |
N (% within grade) |
N |
N (% within grade) |
N (% within grade) |
N |
|||
| High Ki67 | 1 (100.0) | 0 (0.0) | 1 | 8 (44.4) | 10 (55.6) | 18 | ||
| Nuclear atypia | 4 (80.0) | 1 (20.0) | 5 | 22 (48.9) | 23 (51.1) | 45 | ||
| Necrosis | 0 (0.0) | 0 (0.0) | 0 | 2 (18.2) | 9 (81.8) | 11 | ||
| Reactive gliosis | 4 (100.0) | 0 (0.0) | 4 | 20 (62.5) | 12 (37.5) | 32 | ||
| Vascular/endothelial proliferation | 2 (66.7) | 1 (33.3) | 3 | 10 (40.0) | 15 (60.0) | 25 | ||
| Increased Cellularity | 3 (50.0) | 3 (50.0) | 6 | 19 (30.2) | 44 (69.8) | 63 | ||